Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon

Thomas E. Lew, Rory Bennett, Victor S. Lin, Ashley Whitechurch, Sasanka M. Handunnetti, Paula Marlton, Yandong Shen, Stephen P. Mulligan, Joshua Misha Lewis Casan, Piers Blombery,

Blood Advances · 2024 · 18 citations · 22 references

DOIFull text

Open access

Concepts

References

22